More on COGT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $39.76 |
|
|||
| Open | $40.05 | ||||
| 52 Wk High | $5.57 | ||||
| 52 Wk Low | $2.90 | ||||
| Day High | $41.17 | ||||
| Day Low | $39.75 | ||||
| P/E | 184.82 | ||||
| EPS | $0.22 | ||||
| Volume | 557,622 | ||||
- Form 4 Cogent Biosciences, Inc. For: Jul 01 Filed by: Ferrante Karen Jean
- Cogent Biosciences files NDA for bezuclastinib in advanced mastocytosis
- Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
- H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
- Stifel Reiterates Buy Rating on Cogent (COGT)
- Cogent Biosciences presents preclinical data on JAK2 inhibitor at EHA
- Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
- Cogent Biosciences reports 65% response rate in mastocytosis trial
- Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
- Form 4 Cogent Biosciences, Inc. For: Jun 09 Filed by: Harwin Peter Evan
Entities mentioned with COGT
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- S3 | View Related Stories »
- Show More...
